Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -5 of 5
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
D4320C00014
EUDRACT No 2007-003227-20, NCT00554229
2.
A Phase III Trial of ZD4054 (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
D4320C00033
NCT00617669
3.
A Phase III Trial of ZD4054 (Endothelin A Antagonist) in Non-Metastatic Hormone Resistant Prostate Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Active
18 and over
Pharmaceutical / Industry
D4320C00015
NCT00626548
4.
ZD4054 in Pain-free or Mildly Symptomatic Patients with Prostate Cancer and Bone Metastases who have Rising Serum Prostate Specific Antigen (PSA)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
D4320C00006
Trial 6, ZD4054, NCT00090363
5.
ZD4054 Phase II Non-Small Cell Lung Cancer Study
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Active
18 and over
Pharmaceutical / Industry
D4320C00035
NCT00745875
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute